High-Risk Melanoma Patients More Likely to Receive Immunotherapy at End of Life
Metastatic melanoma patients at the highest risk of death are more likely than lower-risk patients to receive immunotherapy near the end of their life.
Metastatic melanoma patients at the highest risk of death are more likely than lower-risk patients to receive immunotherapy near the end of their life.
A 12-week app-based exercise program reduced depressive symptoms in health care professionals, but adherence to the program declined over time.
Changes to taste and smell in women with breast cancer undergoing chemotherapy have a negative impact on quality of life, researchers found.
New research suggests that a mobile app may help patients with multiple myeloma or chronic lymphocytic leukemia manage their symptoms.
For the entire cohort of pediatric patients with standard-risk acute lymphoblastic leukemia, overall survival at 6 years was greater than 95%.
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Induction therapy with blinatumomab did not appear to confer a survival benefit, though undergoing stem cell transplant did.
The TEAMM trial sought to assess time to first febrile episode or death from all causes in patients with newly diagnosed myeloma who received antibiotic prophylaxis vs those who did not.
Researchers determined the 5-year overall and disease-free survival for patients with CSCC of the head and neck who received adjuvant radiation therapy.
Mental health disorders may be an adverse effect of head and neck cancer diagnosis, treatment, or treatment morbidities.